Abveris is a leading antibody discovery company based in Canton, MA, specializing in the development of biologics for therapeutic and reagent antibody targets. With a strong reputation for delivering outstanding science, Abveris offers industry-leading antibody discovery solutions for challenging classes of targets, including cell surface receptors and difficult-to-target molecules such as GPCR and ion channels. Their end-to-end antibody discovery technologies, including repertoire generation, advanced screening, characterization, and recombinant expression, enable them to provide custom-built solutions for biotech and biopharma companies of all sizes.
With expertise in antibody discovery and a fee-for-service, royalty-free partnership model, Abveris supports the development efforts of their partners in various fields, including cell therapies, point-of-care diagnostics, and clinical trials. Their proprietary hyperimmune mouse model, DiversimAb approach, and humanized mice enable rapid and high-resolution single B cell screening, epitope binning, and on-cell binding assays. Abveris' commitment to delivering high-quality clones and analytical data, along with their collaborative spirit, has earned them the trust of pharmaceutical and biotech companies in their pursuit of effective antibody discovery.
Generated from the website